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Background. Glioblastoma (GBM) is the most common and the most malignant glioma subtype. Among numerous 
genetic alterations, miRNAs contribute to pathogenesis of GBM and it is suggested that also to GBM recurrence and 
resistance to therapy. Based on publications, we have selected 11 miRNAs and analyzed their expression in GBM. We 
hypothesized that selected miRNAs are differentially expressed and involved in primary as well as in recurrent GBM, 
that show significant expressional differences when different treatment options are in question, and that are related 
to certain patients and tumor characteristics.
Patients and methods. Paraffin embedded tissues, obtained from primary and corresponding recurrent tumor from 
83 patients with primary GBM were used. Eleven miRNAs (miR-7, miR-9, miR-15b, miR-21, miR-26b, miR-124a, miR-199a, 
let-7a, let-7b, let-7d, and let-7f) were selected for qPCR expression analysis. For patients who received temozolamide 
(TMZ) as chemotherapeutic drug, O6-methylguanine-DNA methyltransferase (MGMT) methylation status was defined 
using the methyl-specific PCR. 
Results. There was a significant change in expression of miR-7, miR-9, miR-21, miR-26b, mirR-124a, miR-199a and let-
7f in recurrent tumor compared to the primary. In recurrent tumor, miR-15b, let-7d and let-7f significantly changed 
comparing both treatment options. We also observed difference in progression free survival between patients that 
received radiotherapy and patients that received radiotherapy and chemotherapy, and longer survival for patients 
who received chemotherapy after second surgery compared to not treated patients. miR-26b showed correlation to 
progression free survival and let-7f to overall survival. We did not find any expression difference between the tumors 
with and without methylated MGMT.
Conclusions. Our data suggest that analyzed miRNAs may not only contribute to pathogenesis of primary GBM, 
but also to tumor progression and its recurrence. Moreover, expression of certain miRNAs appears to be therapy-
dependent and as such they might serve as additional biomarker for recurrence prediction and potentially predict 
a therapy-resistance. 
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Introduction
Gliomas are the most common primary brain tu-
mors and are classified on the basis of histopatho-
logical characteristics. Glioblastoma (GBM) is the 
most common and malignant glioma subtype 
characterized by rapid growth and poor prog-
nosis.1 Like cancer in general, GBM develop as a 
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consequence of genetic alterations that accumulate 
with tumor progression. However, pathogenesis of 
GBM recurrence is still poorly understood. Certain 
molecular pathways and novel biomarkers have 
been established as diagnostic, prognostic and pre-
dictive markers, such as is epidermal growth factor 
receptor (EGFR) amplification, O6-methylguanine-
DNA methyltransferase (MGMT) methylation and 
others.1-3 Among novel biomarkers are non-coding 
RNAs, of which the most studied are microRNAs 
(miRNAs). The miRNAs are small RNAs that act 
as endogenous regulators of gene expressions and 
function in different physiological processes, con-
tributing to pathogenesis of different types of can-
cer, including gliomas. miRNA expression might 
be a potential biomarker for GBM used as diag-
nostic support or for prognostic and therapeutic 
application.4-6 However, differential expression of 
certain miRNAs might be also involved in patho-
physiological mechanisms of GBM recurrence, 
but there are limited data regarding miRNA ex-
pression as GBM progresses (at its recurrence).7,8 
Comprehensive knowledge and understanding of 
the molecular pathways underlying disease pro-
gression, tumor recurrence and response to thera-
py might be of great importance in future develop-
ment of more efficient therapies in GBM. 
Local infiltration and progressive growth of 
GBM tumor cells into the adjacent brain tissue in-
validate any possibility for a radical surgical tumor 
resection.9 Consequently, recurrence is observed in 
almost all tumors.7 Additionally, the difficulty in 
treatment of this lethal disease is in tumor acqui-
sition of several mechanisms of radio and chemo-
resistance. In addition to methylation of MGMT10, 
a change in miRNA’s expression is also a cause for 
drug resistance in GBM.11 Several miRNAs have 
been related to radio- and chemo-sensitivity as 
well as radio- and chemo-resistance of glioma cells, 
and recognized as crucial regulators during glioma 
pathogenesis and progression.12 However, a cer-
tain degree of this aberrant regulation may also be 
the consequence of treatment. 
In aim to characterize at least some miRNAs that 
might be involved in GBM formation/progression 
and recurrence, and may also contribute to therapy 
resistance, we selected 83 consecutive patients with 
operable recurrent GBM, where samples from first 
and from second surgery were available. We select-
ed ten miRNAs, which expression was up-regulated 
(miR-9, miR-15b, miR-21, miR-26b, let-7a, let-7b, let-7d 
and let-7f) or down-regulated (miR-7 and miR-124a) 
in previous studies of GBM, and were differentially 
expressed from other glioma subtypes.13 We addi-
tionally included miR-199a, which is involved in 
tumorigenesis of various types of cancer, including 
GBM.14 The majority of these miRNAs have already 
been shown to be involved in different tumorigenic 
processes in GBM or glioma cell lines (Table 1).4,15 
We hypothesized that: (i) selected miRNAs are de-
regulated in primary as well as in recurrent GBM; 
(ii) some miRNAs are also differently expressed 
between primary and recurrent tumor; (iii) expres-
sion of selected miRNAs in recurrent GBM is ther-
apy dependent; (iv) progression free survival and 
overall survival is different between distinct thera-
pies; (v) expression of some miRNAs is related to 
progression free survival and overall survival; and 
TABLE 1. List of the analysed miRNAs with known functions in glioma pathogenesis
MicroRNAs Invasion Proliferation Tu growth Migration Cell cycle Survival/cell death Other functions
miR-7 + + + nd + + Differentiation, Vasculogenic mimicry
miR-9 nd + nd + nd nd Self-renewal,  Vasculogenic mimicry
miR-15b + + + nd + + Angiogenesis
miR-21 + + + + + + /
miR-26b + + + + nd + Vasculogenic mimicry
miR-124 + + + + + + Differentiation, Angiogenesis
miR-199a nd + nd nd nd nd /
let-7a nd + + + nd nd /
let-7b + nd nd + nd nd /
let-7d nd nd nd nd nd nd /
let-7f + + nd + nd nd /
+ = involved in tumorigenic process in glioma; nd = not determined yet as involved in tumorigenic process; Tu = tumor; reviewed from Karsy et al.4, 
Lages et al.13, Silber et al.5, Visani et al.40, Zhang et al.6
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(vi) methylation status of MGMT is in correlation to 
certain miRNAs.
Patients and methods
Patients and tissue samples
Our retrospective study included eighty-three pa-
tients with recurrent GBM. The data were obtained 
from the patients charts from hospital registry of 
the Institute of Oncology and from the Cancer 
Registry of Slovenia. Each patient underwent the 
first surgery and the second one after the first 
recurrence of GBM between January 1997 and 
November 2011 at the University Clinical Centre 
Ljubljana, Slovenia. The selected patients were 
consecutive; of the 1117 that underwent the first 
surgery for GBM, 83 underwent also the second 
surgeryat tumor recurrence since these patients 
were capable of re-operation according to clini-
cal standards (Karnofsky performance status over 
80). Patients received radiotherapy (RT) after the 
surgery, and RT with concomitant and adjuvant 
chemotherapy (ChT) after 2005. 
Tissue samples were fixed in 10% buffered forma-
lin and embedded in paraffin (FFPE) for routine di-
agnostics. The grading criteria based on WHO clas-
sification was used.14 Paired tissue samples were re-
trieved from the archive of the Institute of Pathology, 
Faculty of Medicine, University of Ljubljana. 
Samples were classified in two groups, i.e. primary 
GBM (sample tissue collected at first surgery) and 
corresponding recurrent GBM (sample tissue col-
lected at second surgery). As control sample RNA 
FirstChoice Human Brain Reference Total RNA (Cat.
no. 6050, Ambion; Invitrogen, USA) was used. 
The patients’ data, including age, gender and 
therapy are summarized in Table 2. 
RNA isolation from FFPE tissue samples 
Tissue samples were cut at 10 μm from FFPE tissue 
blocks and for the isolation procedure six to eight 
10 μm sections were used. Total RNA isolation 
was performed using miRNeasy FFPE Kit (Qiagen, 
Germany) according to the manufacturer’s pro-
tocol. The RNA was eluted in 30 μl of nuclease-
free water. The yield was measured spectropho-
tometrically using the NanoDrop-1000 (Thermo 
Scientific, USA) and the quality was evaluated on 
the Bioanalyzer 2100 (Agilent Technologies, USA). 
Quantitative real-time PCR (qPCR) 
All the reagents were from Qiagen, except where 
otherwise indicated. Quantitative PCR (qPCR) was 
carried out using the Rotor Gene-Q Real-Time PCR 
System and all the qPCR reactions were performed 
in duplicates or triplicates. Prior to qPCR analysis, 
two pools of RNA samples were created from FFPE 
tissue samples (primary, recurrence) and, along 
with reference RNA, tested for qPCR efficiency. 
Reverse transcription using miScript reverse tran-
scription kit was performed in a 10 μl reaction 
master mix with 50 ng of total RNA according to 
manufacturer instruction. The resulting cDNA was 
diluted 100-fold and qPCR reaction was carried out 
in 10 μl PCR master mix, according to manufactur-
er instruction. As the reference genes, RNU6B and 
SNORD25 were used based on efficiency results. 
Tested miRNAs were: miR-7, miR-9, miR-15b, miR-
21, miR-26b, miR-124a, miR-199a, let-7a, let-7b, let-7d, 
and let-7f.
DNA isolation 
In a subset of patients that were treated with temo-
zolamide (TMZ) (n = 47), MGMT methylation sta-
tus was determined. Tissue samples from the first 
surgery and the surgery at first recurrence were cut 
at 10 μm from FFPE tissue blocks and for the iso-
lation procedure, six to eight 10 μm sections were 
TABLE 2. Demographic and clinicopathological characteristics of patients included 
in the study
Histopathological diagnosis GBM, WHO grade IV
Number of cases 83
Mean age (Year) 50 ± 12.8 (min 8, max 71) 
Gender
Male 50 (60%)
Female 33 (40%)
Karnofsky performance status ≥ 80 83
Adjuvant treatment
radiotherapy after first surgery 83/83 (100%)
chemotherapy after first surgery 54/83 (65%)
radiotherapy after second surgery 15/83 (18%)
chemotherapy after second surgery 47/83 (56%)
MGMT methylated 
(tested in a subset 
of patients treated 
with TMZ)
Primary GBM 38/47 (81%)
Recurrent GBM 46/47 (98%)
Time to recurrence (months) 0.84–67.30
Survival after second surgery (months) 0.03–25.75
Overall survival (months) 0.84–70.48
MGMT = methyl guanine methyl transferase; TMZ = temozolamide
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used. Total DNA isolation was performed using 
QIAamp DNA FFPE Tissue Kit (Qiagen) according 
to the manufacturer’s protocol. The DNA was elut-
ed in 60 μl of nuclease-free water. The yield was 
measured fluorescently using the Quant-It (Life 
Technologies) according to manufacturer instruc-
tion and Rotor Gene Q (Qiagen).
MGMT methylation status analysis 
For determining the MGMT methylation status, 
methyl-specific polymerase chain reaction (MSP) 
was used in a two-step approach with primers 
previously described.16 Briefly, prior to MSP, 500 
ng of DNA was used for bisulfite conversion us-
ing innuCONVERT Bisulfite Basic Kit according 
to manufacturer instruction (Analytik Jena) and 
stored at -20°C for subsequent MSP. For MSP, 15 
ng of bisulfite converted DNA was used with 0.2 
μM of each primer for methylated form and 0.3 
μM of each primer for unmethylated form, 2 mM 
of dNTP and 0.25 U of Hot Master Polymerase (5 
Prime), all in 10 μl reaction. Amplification was per-
formed according to manufacturer instruction us-
ing 59°C for primer annealing. In each run, fully 
methylated (EpiTect Control DNA, methylated, 
Qiagen) as well as fully unmethylated controls 
(EpiTect Control DNA, unmethlyated, Qiagen) 
were used as assay controls. Results were analyzed 
using 2% agarose gel. The investigator who ana-
lyzed the GBM samples was blinded to all clinical 
information.
Statistical analysis
To present a relative gene expression the 2-ΔΔCt 
method was used.17 For paired samples (primary, 
recurrent), the calculated ΔCt was tested for sta-
tistical significance using Wilcoxon Signed Rank 
test. For independent group of samples, ΔΔCt was 
calculated relatively to Human brain Reference 
RNA and used for Mann-Whitney test (treat-
ment, MGMT status, etc.). Kaplan-Meier curve 
was used to analyze difference in progression free 
survival (time to recurrence) and overall survival 
(different treatment options, miRNA expression). 
Correlations between scale variables (miRNA ex-
pression, survival) were calculated using Pearson’s 
and Spearman’s correlation coefficient. For all sta-
tistical tests, the SPSS analytical software (ver.24 
SPSS Inc. IL) was used (cut-off point at p < 0.05). 
The workflow of comparisons is summarized in 
Figure 1.
Compliance with ethical standards
Study has been approved by Slovene National 
Medical Ethics Committee (Number 113/05/13).
Results
Expression of miRNAs is changed in 
primary and recurrent GBM
Comparing expression of analyzed miRNAs to 
Human Brain Reference RNA (ΔΔCt), we found al-
tered expression for all 11 analyzed miRNAs both 
in primary as well as in recurrent GBM. Whereas 
miR-9 and miR-21 were mainly up-regulated and 
miR-15b was mainly down-regulated in primary 
and recurrent GBM, all other miRNAs showed 
more heterogeneous expression when compared 
to the Human Brain Reference RNA. Results are 
summarized in Figure 2.
miRNAs in recurrent GBM are 
differentially expressed compared to 
primary GBM
Using calculated ΔCt and Wilcoxon Signed Rank 
test, we have observed significant alteration in 
expression for 7 miRNAs between primary and 
recurrent GBM. Five miRNAs, miR-9 (p = 0.016), 
miR-21 (p < 0.001), miR-26b (p < 0.001), miR-124 (p 
Tissue
samples
Newly diagnosed
GBM
Treatment with
radiotherapy
Treatment with
radio- and
chemotherapy
Recurrent
GBM
Treatment with
radiotherapy
Treatment with
radio- and
chemotherapy
Reference
RNA
Reference
RNA1 1
33
2
4
FIGURE 1. Schematic representation of the workflow and 
statistical comparisons.
GBM = glioblastoma; Reference RNA = Human Brain Reference RNA; 
1 = Willcoxon Signed Rank Test between primary glioblastoma and 
corresponding recurrent glioblastoma using ΔCt; 2 = normalization to 
Human Brain reference RNA resulting in ΔΔCt; 3 and 4 = Mann-Whitney 
test between independent groups of samples using ΔΔCt (normalization 
of glioblastoma samples to Human Brain Reference RNA)
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FIGURE 2. Expression of miRNAs in primary and recurrent GBM (compared to the Human Brain Reference RNA, ΔΔCt) with Table presenting Average 
Fold Changes. 
ChT = chemotherapy; RT = radiotherapy; A = primary GBM; B = recurrent GBM
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= 0.029) and miR-199a (p < 0.001), were down-reg-
ulated, and miR-7 (p = 0.001) and let-7f (p < 0.001) 
were up-regulated in recurrent tumors compared 
to first time surgery. However, all of these miR-
NAs were differentially expressed also in a sub-
group treated with RT and ChT, whereas only four 
of these showed statistically significant differential 
expression in a subgroup treated with RT alone. 
Results are summarized in Figure 3 and Figure 2 
(Average Fold Change Table).
Distinctive expression of miRNAs after 
different treatment options in recurrent 
GBM
Using Mann-Whitney test for comparing sub-
group of patients treated with RT alone to pa-
tients treated with RT and ChT (analyzed miR-
NAs normalized to Human Brain Reference RNA, 
ΔΔCt), we observed that expression of certain 
miRNAs was different before treatment (at first 
surgery) as well as after treatment (at second sur-
gery). Therefore, only those miRNAs that showed 
significantly differential expression only after 
treatment (at second surgery) were considered 
truly as a consequence of treatment. Both miR-
15b and miR-7d were down-regulated compared 
to Human Brain Reference RNA after treatment, 
and there was significant change in expression be-
tween patients that received RT alone and those 
that received RT and ChT (p = 0.013 for miR-15b 
and p = 0.008 for let-7d). In patients treated with 
RT alone, let-7f was up-regulated compared to 
Human Brain Reference RNA at second surgery, 
whereas it was unchanged in patients that were 
treated with RT and ChT. There was significant 
change in expression of let-7f between both groups 
(p = 0.007). Results are summarized in Figure 4.
Correlation between progression free 
survival, survival after second surgery, 
overall survival, treatment and miRNA 
expression
There was weak, but statistically significant change 
in progression free survival between patients who 
received RT alone and those who received both, 
RT and ChT after first surgery (7 months and 11 
months, respectively; p = 0.045). Results are sum-
marized in Figure 5A.
We have also calculated the survival time from 
second surgery. The number of patients who re-
ceived RT alone or RT and ChT was too small for 
reliable analysis of survival time. However, there 
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FIGURE 3. Expression of miRNAs in recurrent glioblastoma (GBM) after treatment 
compared to expression in primary GBM. Results are represented separately for 
patients treated with RT and those treated with RT and ChT.
ChT = chemotherapy; RT = radiotherapy; * = significant differences in expression of miRNAs, 
p < 0.05; ** = p < 0.01
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recurrent glioblastoma
ChT = chemotherapy; RT = radiotherapy; * = p < 0.05; ** = p < 0.01
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was statistically significant longer overall sur-
vival for patients who received ChT compared to 
those that were not treated after second surgery 
(8 months and 5 months, respectively; p = 0.004). 
Results are summarized in Figure 5B.
We further calculate Spearman’s and Pearson’s 
correlation coefficient between miRNA expression 
(analyzed miRNAs normalized to Human Brain 
Reference RNA, ΔΔCt) in primary GBM and pro-
gression free survival and overall survival, and 
found weak inverse correlation for let-7b and pro-
gression free survival (r = -0.220, p = 0.049) and 
weak inverse correlation between let-7f and overall 
survival (r = -0.226, p = 0.050). We further analysed 
difference in Kaplan-Meier curve for patients with 
up- and down-regulated miRNAs and found, that 
there is a difference in progression free between 
patients with up- and down-regulated miR-26b (p = 
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0.05, Figure 5C), and difference in overall survival 
for up- and down regulated let-7f (p = 0.021).
miRNAs and MGMT methylation status
Among patients treated with ChT, there were 47 
treated with TMZ. Among them, there were 9 pa-
tients with unmethylated and 34 with methylated 
MGMT. All, except one, became methylated in 
recurrent tumor. Comparing miRNA expression 
normalized to Human Brain Reference RNA be-
tween MGMT methylated and MGMT unmethyl-
ated tumors revealed no correlation of investigated 
miRNA expression to MGMT methylation status. 
Discussion
In our 83 consecutive patients operated for pri-
mary GBM and re-operated at the first recurrence 
of GBM, we have analyzed the expression of 11 
selected miRNAs (miR-7, miR-9, miR-15b, miR-21, 
miR-26b, miR-124a miR-199a, let-7a, let-7b, let-7d, 
and let-7f). However, to the best of our knowledge, 
this is the first report of these miRNAs expression 
in recurrent GBM. 
Expression of analyzed miRNAs in 
primary and recurrent GBM
We observed differential expression of the majority 
of analyzed miRNAs in both samples. In primary 
as well as in recurrent GBM we have observed 
overall miR-7 over-expression, although was ex-
pression heterogeneous among tumors. In spite 
of numerous studies on miR-7 expression, its ex-
pression in recurrent GBM has not been analyzed 
yet. Increased expression of miR-7 was found to 
suppress GBM cell proliferation, induce apopto-
sis, inhibit cell migration in vitro, and reduce tu-
morigenicity in vivo.4 However, in contrast to our 
study, other research group showed miR-7 down-
regulation in patients with GBM.18 Possible expla-
nation for different outcomes might be in different 
normalization strategies used for qPCR (i.e. differ-
ent reference genes used). miR-9 over-expression, 
observed in our primary and recurrent GBM sam-
ples, might contribute to tumor progression since 
it has been identified that up-regulation of miR-9 
predicts an unfavorable prognosis and correlates 
with tumor progression.19 Similarly to other can-
cer research20, we observed increased expression of 
oncogenic miR-21 in primary and recurrent GBM, 
although its’ up-regulation in recurrent tumors is 
significantly lower compared to primary tumors. 
miR-26b was also found to be mainly over-ex-
pressed, although there are samples with its down-
regulation, but in contrast to our results, it has been 
shown that miR-26b was decreased in glioma cell 
lines and inversely correlated with the grade of gli-
oma in humans.21 The discrepancy could be due to 
different normalization strategies. We normalized 
expression of miRNAs in GBM samples to Human 
Brain Reference RNA, in others the normal brain 
tissue was used for normalization.21 Expression of 
miR-124a in our research showed up-regulation in 
certain samples of primary tumors. Published data 
showed decreased miR-124a expression in major-
ity of GBM samples due to hyper-methylation of 
promoter region of miR-124a.22 Speculatively, dif-
ferent methylation status of miR-124a might be ob-
served in our samples. We also observed mainly 
higher expression level of miR-199a in primary 
GBM samples and near to normal level in recur-
rent GBM. miR-199a up-regulation in gliomas has 
been related to hypo-methylation of one of two 
copies of miR-199a within genome consequently 
leading to its up-regulation.14 miR-199a is believed 
to have diverse biological functions in different tis-
sues. It behaves as a tumor-suppressor in certain 
cancer types14; however, its exact role in GBM is yet 
to be defined. miRNA of let-7 family (let-7a/b/d/f) 
showed the most heterogeneous expression across 
both, primary and recurrent tumor samples.15,23
Expression of miRNA in recurrent and 
primary GBM and its correlation to the 
choice of therapy
Our data also showed statistically significant alter-
ation of expression of seven miRNAs (miR-7, miR-
9, miR-21, miR-26b, miR-124a, miR-199a and let-7f) 
between primary and recurrent tumors. After re-
ceiving RT and ChT, we observed higher levels of 
miR-7 in recurrent compared to the primary GBM, 
whereas in patients treated solely using RT there 
was no significant difference in expression. Based 
on glioma cell line models, up-regulation of miR-
7 increases radio-sensitivity.24 Several target genes 
that might be involved in sensitivity of glioma cells 
to therapy has been shown for miR-7, including 
EGFR, IRS1 and IRS2 regulating differentiation, 
invasion and proliferation4, as well as IGF-1R/Akt 
signalling pathway, regulating cellular growth 
and glucose metabolism in gliomas.25,26 We did 
observe a decreased expression of miR-9 in recur-
rent compared to primary GBM, however, miR-9 is 
still over-expressed in recurrent GBM. miR-9 has a 
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role in chemotherapeutic resistance by regulating 
the p38 mitogen activated protein kinase signal-
ing network, involved in regulation of cell stress 
and cell differentiation; it influences proliferation 
and self-renewal of glioma cells by targeting SOX2; 
and through miRNA regulation of PTCH1, recep-
tor in Sonic Hedgehog signaling.26 miR-21 has been 
shown to be up-regulated in more radio-resistant 
cell lines 12 mediating the resistance of GBM cells 
against RT27 and TMZ.20 miR-21 is substantially 
implicated in pathogenesis of GBM by targeting 
PTEN, RECK, PDCDC4, TIMP3, BCL2, SPRY2, 
MTAP, SOX5, JMY, TGFRBR2, TGFBR3, TP73L, 
APAFI, BMPR2, TOPORS, DAXX, TP53BP2, and 
PPIF. All this target genes are involved either in 
pathways of apoptosis, invasion, proliferation 
and tumor growth either in chemo-resistance.4 
Therefore, all these results suggest that lower ex-
pression of miR-21 after treatment might implicate 
less resistant glioma cells to therapy; however, as 
well as miR-9, it is still up-regulated in recurrent 
GBM, possibly contributing to tumor progression.
Decrease expression of miR-26b in our recurrent 
samples compared to primary GBM, could be a 
consequence of tumor progression. Accordingly, it 
was found that ectopic expression of miR-26b inhib-
its proliferation, migration and invasion of human 
glioma cells by repressing the endogenous level of 
EphA2 protein.21 We further observed decrease in 
miR-124a expression in recurrent tumors compared 
to primary, which might be a consequence of tu-
mor progression. It has been shown that miR-124a 
radio-sensitizes human glioma cells by targeting 
CDK4.28 Several other targets have been also dem-
onstrated for miR-124a, as are CDK6, SCP1, PTBP1, 
ITGB1, LAMCI, IQGAPI, RB and STAT3, regulat-
ing cell cycle, differentiation, invasion and prolifer-
ation of glioma cells and T cell-mediated immune 
clearance of glioma.4,29 All these processes may be 
involved in sensitivity and survival of glioma cells.
In recurrent GBM, but not in primary GBM, 
we found significant change in expression be-
tween samples of patients who were treated with 
RT and ChT and those that were treated with RT 
alone for only miR-15b, let-7d and let-7f. Let-7f was 
over-expressed in recurrent compared to the pri-
mary GBM; however, it was up-regulated only in 
patients treated with RT after first surgery. It has 
been shown that members of let-7 miRNA family 
(including let-7f) were mostly up-regulated in more 
Resistance/sensi?vity 
of glioma to Th. 
miR-7 down-
regula?on. 
Up-regulation of target,  
cyclin D1. 
miR-21 up-regulation. 
Up-regula?on of target, 
CDK4 .
miR-124 down-regula?on. 
Radio-resistance and poor 
prognosis. 
Up-regula?on of target, 
EGFR. 
Radio-resistance. 
let-7b down-regulation.  
Chemo- resistance to 
cispla?n. 
Chemo-resistance to VM-
26, Taxol, 5-FU, TMZ. 
Down-regula?on of 
targets: LRRFIP1, STAT3, 
BAx/Bcl-2/caspase3. 
A?er RT, accumula?on of 
cells in G2-M of cell cycle. 
let-7a down-regula?on 
a?er RT in MO59J and up-
regula?on a?er RT in 
MO59K. 
Radio-resistance, inverse 
correla?on to expression 
of miR-21. 
FIGURE 6. Summary of known functions in radio- and chemoresistance and sensitivity of miRNAs analyzed in our study.
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radio-resistant cell lines12 suggesting radio-resist-
ant function in glioma cells, since its expression 
after receiving RT and ChT was back to normal. 
There was observed normal expression of let-7d in 
GBM patients after receiving RT, however, after 
treating patients with RT and ChT, its expression 
was decreased and similar to that in primary GBM. 
There are limited data about the role of let-7d in the 
cell response to radiation and chemotherapeutic 
drugs in glioma, since depends on dose, time after 
irradiation and source of oxidative stress.30 There 
are indication that let-7d down-regulation in GBM 
might be involved in modulation of chemo-resist-
ance to TMZ.11 One of the target genes of let-7d is 
oncogene HMGA231 and studies suggest that over-
expression of HMGA2 may participate in regulat-
ing tumor cell invasion in high grade gliomas.32 
However, whether HMGA2 is up-regulated in 
GBM due to let-7d down-regulation, is yet to be de-
fined. Another miRNA, miR-15b, was found in our 
study to be significantly under-expressed in pa-
tients treated with RT and ChT compared to those 
treated with RT alone. Similarly, to let-7d, decrease 
of miR-15b did not change in recurrent GBM com-
pared to primary GBM. miR-15b was demonstrated 
to suppress proliferation and induce apoptosis in 
glioma cells by targeting CCNE1.33 miR-15b expres-
sion decreases with the ascending histopathologi-
cal grade and its low expression is associated with 
poor overall survival of patients with high grade 
gliomas.34 Already known functions about radio- 
and chemoresistance/sensitivity and analyzed 
miRNAs are summarized in Figure 6.
Time to recurrence, survival and overall 
survival in correlation to therapy and 
miRNA expression
Finally, in our patients we have observed longer 
disease free survival in patients treated with RT 
and ChT after first surgery compared to those treat-
ed with RT alone. The standard care treatment of 
GBM altered importantly after year 2005 when RT 
alone was replaced by RT associated with chemo-
therapeutic TMZ in great majority of our patients. 
Similarly to our results, it has been shown that for 
patients treated with surgery and RT alone median 
survival was shorter (12–12.1 months)  compared 
to patients treated additionally with TMZ (14.2–
14.6 months).35
Investigating miRNAs expression and survival 
in patients with GBM revealed that, both, miR-26b 
and let-7f represent better prognosis when down-
regulated. Lower expression of miR-26b is in corre-
lation to progression free survival, whereas lower 
expression of let-7f is in correlation to overall sur-
vival. To the best of our knowledge, this is the first 
report describing expression of these two miRNAs 
to the function of survival in the GBM.
MGMT and miRNAs
Although we did not found any differential ex-
pression of investigated miRNAs between methyl-
ated and unmethylated MGMT, we did observed 
change in MGMT methylation status from primary 
to recurrent GBM. Eight of nine unmethylated 
samples in primary GBM were methylated in re-
current GBM. This change in methylation status 
of MGMT is not surprising, since there are sev-
eral publications describing similar percentage of 
change; however all changes were from more to 
less favorable state for tumor progression.36-39 
Conclusions
In conclusion, our results suggest that in recurrent 
GBM patients, miRNAs might play important role 
not only in pathogenesis of GBM, but also in tu-
mor progression and its recurrence, as well as in 
response to therapy, in overall survival and pro-
gression free survival. 
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